-
70
-
59
-
40
-
35
-
30
Guidelines
Below is a list of CUA Guidelines, Best Practice Reports (BPRs), CUA-Endorsed Guidelines, and Consensus Statements.
Full-length guidelines are reserved for broader topics that require more comprehensive exploration. BPRs provide a more focused, concise summary of the best evidence available on common urological topics to help guide management decisions. Both formats have undergone official CUA guideline approval process. Where possible, the GRADE approach for summarizing thttps://cuaj.ca/index.php/journal/article/view/8161/5547he evidence and making recommendations has been used.
The CUA-endorsed guidelines have been developed by other associations and endorsed by the CUA Guidelines and Endorsement Committees.
Reproduction of any part of the published CUA guidelines, consensus statements, and best practice reports requires the express written consent of the Canadian Urological Association (CUA).
CUA GUIDELINES
- Management of cystic renal lesions, June 2023
- Diagnosis, management, and followup of the incidentally discovered adrenal mass, February 2023
- UPDATE 2022 - CUA/CUOG: Metastatic castration-naive and castration-sensitive prostate cancer, December 2022
- UPDATE 2022 - CUA/CUOG: Castration-resistant prostate cancer, November 2022
- UPDATE 2022 - Male lower urinary tract symptoms/benign prostatic hyperplasia, August 2022
- UPDATE 2022 - ADT: Adverse events and management strategies, August 2022
- Testicular germ cell cancer, June 2022
- Evaluation and medical management of kidney stones, June 2022
- UPDATE 2022 - Prostate cancer screening and early diagnosis: Endorsement of 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging, April 2022
- Small renal masses - Full-text, February 2022
- Small renal masses - Summary of recommendations, February 2022
- Ureteral calculi - Abridged version, December 2021
- Erectile dysfunction, October 2021
- Non-muscle-invasive bladder cancer, August 2021
- Muscle-invasive bladder cancer, August 2019
- Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Executive summary, June 2019
- Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text, June 2019
- AUA/CUA/SUFU: Recurrent uncomplicated urinary tract infections in women, May 2019
- Perioperative thromboprophylaxis and management of anticoagulation, April 2019
- Followup of patients after treatment of non-metastatic renal cell carcinoma, August 2018
- Peyronie's disease and congenital penile curvature, May 2018
- CUA/PUC: Investigation and management of antenatally detected hydronephrosis, April 2018
- Care of the normal foreskin and neonatal circumcision in Canadian infants (full version), February 2018
- Care of the normal foreskin and neonatal circumcision in Canadian infants (abridged version), February 2018
- CUA/PUC: Diagnosis, management, and followup of cryptorchidism, July 2017
- Adult overactive bladder: Full text, May 2017
- Adult overactive bladder: Executive summary, May 2017
- Diagnosis and treatment of interstitial cystitis/bladder pain syndrome, May 2016 (Update pending)
- Multicystic dysplastic kidney (MCDK) in the neonate: The role of the urologist, February 2016
- Postoperative surveillance of upper urinary tract urothelial carcinoma, October 2013 (Update pending)
- Genetic screening for hereditary renal cell cancers, October 2013
- Prostatitis, October 2011 (Update pending)
- Prostate biopsy methodology, April 2010
- Followup after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma, February 2009
CUA BEST PRACTICE REPORTS
- Nocturia, July 2022
- UPDATE 2022 - Vasectomy, May 2022
- Bone health in prostate cancer, December 2021
- Holmium: YAG laser eye safety, December 2020
- Diagnosis and management of sporadic angiomyolipomas, November 2020
- Pediatric hemorrhagic cystitis, November 2019
- Diagnosis and management of radiation-induced hemorrhagic cystitis, February 2019
- Chronic scrotal pain, June 2018
CUA-ENDORSED GUIDELINES
- CCO: Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer, February 2022
- NSWOCC/UNC: Urinary diversions position statement, January 2022
CONSENSUS STATEMENTS
- CKCF: Adjuvant therapy for renal cell carcinoma, May 2023
- KCRNC: Management of advanced kidney cancer 2021 update, April 2021
- CUA/GUMOC: Management of urachal cancer, March 2020
- KCRNC: The role of renal mass biopsy in the management of kidney cancer, December 2019
- Erectile rehabilitation following prostate cancer treatment, August 2019
- KCRNC: The role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma, June 2019
- KCRNC: The role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials, June 2018
- CKCF: Management of advanced kidney cancer (2017 update), October 2017
- Structured assessment and followup for patients with hereditary kidney tumour syndromes, July 2016
- CUA/BCC/CUOG: Recommendations for the improvement of bladder cancer quality of care in Canada, February 2016
- CKCF: Surgical management of renal cell carcinoma, June 2014
- CAGMO: Management of carcinoma of the penis, November 2013
- CAGMO: Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC), October 2013
- CAGMO: Management of small cell carcinoma of the bladder, February 2013
- 2012 update: Adult Urinary Incontinence Collaborative Consensus, October 2012
- Canadian Consensus Conference: The FDA decision on the use of 5ARIs, April 2012